This grant funds research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy to determine optimal use of these modalities in characterizing therapy response and emergence of resistance. Clinical trials are optional, enabling diverse study designs focused on improving cancer treatment monitoring.
Eligible applicants include a wide range of U.S. organizations such as public housing authorities, nonprofits (with or without 501(c)(3) status), for-profit organizations excluding small businesses, various government entities, educational institutions, tribal organizations, and special districts. S
